149366-79-0Relevant articles and documents
Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors
Pajouhesh, Hassan,Feng, Zhong-Ping,Zhang, Lingyun,Pajouhesh, Hossein,Jiang, Xinpo,Hendricson, Adam,Dong, Haiheng,Tringham, Elizabeth,Ding, Yanbing,Vanderah, Todd W.,Porreca, Frank,Belardetti, Francesco,Zamponi, Gerald W.,Mitscher, Lester A.,Snutch, Terrance P.
scheme or table, p. 4153 - 4158 (2012/07/14)
We previously reported the small organic N-type calcium channel blocker NP078585 that while efficacious in animal models for pain, exhibited modest L-type calcium channel selectivity and substantial off-target inhibition against the hERG potassium channel
3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS
-
Page 14; 26, (2008/06/13)
The invention relates to compounds that are derivatives of 3-aminomethyl-pyrrolidine of the formulas: wherein: Y is (X2)1A or (X1)mCR4A2; W is CR4 or N; R1-R4 are noninterfering substituents; n is 0-7; 1 and m are independently 0 or 1; X1-X2 are linkers;
BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE
-
Page 79; 80, (2010/02/04)
The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.